Report Categories
View AllRecent Articles
View All
Companies Double Down on Prediction Market Investments Amid Regulatory Uncertainty
Firefly FLY Stock Surges 15 on Rosy Space Sector Outlook
SpaceX Launches Starship on Second Attempt Advancing NextGeneration Spaceflight Capabilities
Bill Gates Discusses Trump Meeting Musks DOGE and Childhood in WSJ Interview Ahead of Source Code Book
Q4 Earnings Season Alkem Labs Bata India Ashok Leyland Among Key Results in Focus
UN Raises Ebola Risk Level to Very High in DR Congo Potential Implications for Regional Markets
OneSpan OSPN Q1 2026 Earnings EPS Surpasses Estimates on Strong Operational Execution
PRHIZ Q1 2024 Earnings Significant EPS Beat Surprises Markets
ECCW Q1 2026 Earnings EPS Slightly Misses Estimates Note Price Edges Lower
RNXT Q1 2026 Earnings EPS Misses Estimates as Company Advances Pipeline
Revelation Biosciences Q1 2026 Earnings EPS Miss Highlights Ongoing PreRevenue Stage
NTIP Q1 2026 Earnings Net Loss of 002 Reported Stock Dips 067
Wolfspeed WOLF Plunges 139 Bearish Momentum Tests Key Support Levels
Boqii Holding BQ Bounces Sharply Potential Breakout Above Resistance
Palomar Holdings PLMR Falls 442 as Support and Resistance Levels Take Center Stage
CanFite Biopharma CANF Slips 32 as Stock Tests Key Support Level
Alignment Healthcare ALHC Holds Steady Near Key Levels as Trading Volume Normalizes
External Links
CEOs Plan Widespread AIDriven Layoffs EntryLevel Roles Most at Risk
NRX Pharmaceuticals Q1 2026 Earnings Wider Loss Despite No Revenue Stock Advances
J and Friends Holdings JF Holds Steady at 101 Amid Tight Trading Range
BGM Group Ltd BGM Edges Higher Amid Light Trading Key Levels to Watch
Old National Bancorp Preferred ONBPO Edges Lower Amid Quiet Session
San Juan Basin Royalty Trust SJT Edges Higher Amid Modest Uptick
Abundia Global Impact Group AGIG Climbs 348 as Stock Approaches Key Resistance at 125
Home Depot HD Surges 25 as Retail Sentiment Strengthens
Telesat Corporation TSAT Shows Resilience with Slight Uptick Testing Key Levels
Kazia Therapeutics KZIA Faces Sharp Decline as Biotech Volatility Resurfaces